Amsterdam Molecular Therapeutics (AMT) Holding N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
06 jan 2011 - 07:03
Statutaire naam
Amsterdam Molecular Therapeutics (AMT) Holding N.V.
Titel
AMT Announces that Steven H. Holtzman Has Resigned as a Member of the Supervisory Board Due to Appointment at Biogen Idec
Bericht
AMT Announces that Steven H. Holtzman Has Resigned as a Member of the Supervisory Board Due to Appointment at Biogen Idec
Amsterdam, The Netherlands – January 6, 2011 – Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in human gene therapy, announced today that effective immediately Mr. Steven Holtzman has resigned from the AMT Supervisory Board as a result of his being appointed Executive Vice President, Corporate Development at Biogen Idec (NASDAQ: BIIB).
AMT thanks Mr Holtzman for his valuable contribution to the Supervisory Board, which has been cut short, and wishes him success in his new role. The Supervisory Board still comprises five members; accordingly AMT will undertake a careful and orderly search for a new Board member with an appropriate blend of expertise and experience.
Gerelateerde downloads
Datum laatste update: 31 december 2025